NDAORAL-21TABLET
Approved
May 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 10-21 is an oral contraceptive combining mestranol (estrogen) and norethindrone (progestin) in a 21-day active tablet regimen. It prevents pregnancy through suppression of ovulation and alteration of cervical mucus and endometrial environment. This product represents a foundational oral contraceptive from the early 1960s era.
LOE Approaching
As LOE approaches, brand team focus shifts from growth to harvest strategy; expect reduced headcount and emphasis on retention and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORTHO-NOVUM 10-21 offers limited career upside; this is a harvesting, not growth, opportunity best suited for operational efficiency and cost management expertise. Career advancement requires mobility to higher-priority products in the broader contraceptive pipeline or Johnson & Johnson portfolio.
Brand ManagerProduct Manager
Worked on ORTHO-NOVUM 10-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.